2/ This cross-sectional population-based survey included a convenience sample of 37,000 kids & adults in King County, Washington, who enrolled online for home self-collection of upper respiratory samples for SARS-CoV-2 testing from Mar-Nov 2020
3/ 37,067 samples were tested & 673 (1.8%) were #sarscov2 positive (1.6% in adults, 3.4% in kids)
Most kids (80%) had a known SARS-CoV-2 +ve contact, & most contacts (68%) were in the same household
But only 41% of SARS-CoV-2 +ve adults (41.4%) reported any known +ve contact
4/ Among 555 SARS-CoV-2–positive participants, 47/123 (38%) kids were asymptomatic vs 31/432 (7%) adults
Also, asymptomatic children were younger than symptomatic children (mean [SD] age, 6.2 [4.5] years vs 8.3 [5.7] years; P < .001)
👉younger kids less likely to have symptoms
5/ When symptomatic, fewer symptoms were reported in kids vs adults
(mean number of symptoms [SD], 1.6 [2.0] vs 4.5 [3.1])
The duration of symptoms was also shorter in kids than in adults
(mean (SD) of 3.8 (3.8) days of symptoms vs 4.9 (4.1) days in symptomatic adults)
6/ The most common signs & symptoms in kids were runny or stuffy nose, fever, headache, and cough, while adults most frequently reported headache, cough, & fatigue
Note that this study was done before the Alpha or Delta variant was circulating in the US
7/ Co-infection with other viruses was rare
Of 555 SARS-CoV-2 +ve swabs, 487 were tested for 24 respiratory pathogens by RT-PCR. Only 3/108 kids (2.8%) had another virus (2 rhinovirus, 1 adenovirus) vs 10/379 adults (2.6%): 7 rhinovirus, 1 adenovirus, 1 enterovirus, 1 influenza
8/ Symptomatic individuals had lower Ct values (corresponding to higher viral RNA levels) than asymptomatic individuals
Also, Ct values (virus levels) were not significantly different btwn symptomatic kids & symptomatic adults or between asymptomatic kids & asymptomatic adults
9/ Accompanying editorial summarises findings & implications in detail
👉 Take home message: children were less frequently symptomatic, had fewer symptoms & shorter duration of symptoms vs adults - all likely to contribute to lower risk of transmission
2/ We assessed all fatalities within 30 days of a positive #SARSCoV2 test in <20 year-olds during Jan-Mar 2022 when national testing was still available. We collected detailed clinical data from multiple sources to ascertain cause of death for each child
3/ During Jan-Mar 2022, there were 46 deaths within 30 days of a positive #SARSCoV2 test & 11 were due to COVID-19
👉All 11 #COVID19 deaths occurred after primary SARS-CoV-2 infection
👉 8/11 (73%) had underlying comorbidities, including 4 with severe neurodisabilities
1/ This is so mportant - thank you @kerpen for tagging me
The US with all its mitigations, vaccine & booster mandates has the same proportion of kids already exposed to #sarscov2 as the UK, which as been accused of “letting the virus rip”
2/ Methods: We used residual samples from kids aged 1–17 years having a blood test as part of their clinical management in 44 hospital trusts in England. Samples were processed using Roche Elecsys assays for i) nucleocapsid (N) antibodies and ii) spike RBD (S) antibodies
3/ The overall national prevalence estimate of #SARSCoV2 antibody seropositivity in 1-17y, weighted by age & NHS region, based on Spike protein (vaccine or infection) increased from
➡️ 48.5% (95% CrI 40.8%–55.1%) during Sep-Oct 2021
to
➡️ 97.2% (95% CrI 93.7%–98.9%) by Sep 2022
1/ Our latest paper on longitudinal follow-up of teens with long covid (CLoCk) is a game changer:
Different teens report the same post-covid symptoms at 0, 6m & 12m after their #SARSCoV2 PCR , irrespective of whether they tested + or - for the virus
2/ Method: we followed up 11-17y with a PCR-positive #SARSCoV2 test compared with matched PCR-negative controls for 12 months after their test. The final cohort included 2,909 cases and 2,177 controls
3/ We found that teens reporting a symptom at baseline (PCR-testing) improved by 6m, with new teens reporting the same symptoms at 6m, who then improved by 12m, with new kids reporting the same symptoms at 12m and so on …. you catch the drift .. 👇
1/ It’s really sad that, when we report that a disease (eg. #covid19) is more severe or fatal in kids with underlying conditions (eg neurodisabilities, immunocompromised), this is taken to mean that such kids are less valued
The truth is exactly the opposite…🧵
2/ It is really important that we identify kids at increased risk of severe outcomes after any condition (eg #COVID19) so we can raise awareness among clinicians, parents & policymakers to be extra vigilant & implement additional strategies protect them 👉journals.plos.org/plosmedicine/a…
3/ When kids with severe neurodisabilities were identified as high-risk in the 1st pandemic wave, the UK recommended #COVID19 vaccines for 12+y kids with severe neurodisabilities as soon as vaccines were licensed in adults - way back in Jan 2021 👉 adc.bmj.com/content/106/12…
2/ We pointed out that there was very little difference in protection against omicron infection between vaccinated & previously infected 5-11y, while infection plus 2 vaccine doses might provide slightly better protection after 4 months (79.4% vs 62.9%)
3/ We then pointed out that #COVID19 hospitalizations were v low in 5-11y irrespective of vaccination status (0.3-0.5%), although we still aren’t sure how these were calculated because numerator/denominator in their table give lower percentages (0.1%)🤷🏻♂️